Novartis’ Rydapt , the first and only targeted therapy approved in Europe for FLT3-mutated acute myeloid leukaemia (AML), has been rejected for NHS use by the National Institute for Health and Care Excellence. In draft guidelines, the cost watchdog highlighted that data from a randomised controlled trial shows people taking Rydapt (midostaurin) with chemotherapy live longer than people taking chemotherapy alone....
READ MORE
|
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease. The results were published this week in the journal Genetics in Medicine. Lynch syndrome is a hereditary condition that results in higher rates of colon, endometrial, and other cancers. If unmanaged, indi...
READ MORE
|
UK-based biopharmaceutical company Mereo BioPharma has announced that its BPS-804 drug has been accepted to participate in the European Medicines Agency’s (EMA) adaptive pathways programme. As part of the adaptive pathways approach, EMA aims to improve timely access for patients to new medicines, primarily in areas of high medical need....
READ MORE
|
The global aptamers market is poised for rapid growth between 2015 and 2020. Factors such as strong trend of R&D investments in biotechnology and pharmaceutical industries, the patent expiration of systematic evolution of ligands by exponential enrichment technology (SELEX), technological advancements, and the low cost and high efficiency of aptamers in binding to large molecules as compared to antibodies are driving the growth of the aptamers market....
WHATECH.COM
READ MORE
|
GlaxoSmithKline has announced that the European Commission has granted marketing authorisation for two new methods of administering the companys Nucala mepolizumab - a pre-filled pen and a pre-filled safety syringe. It is the only monthly anti-IL5 biologic approved in Europe that people with severe eosinophilic asthma can take at home, after a healthcare professional decides it is appropriate. The first European launches of the new administration options are expected to take place in August 2019...
READ MORE
|
M Pharmaceutical Inc., (the "Company" or “M Pharma”), is pleased to announce that it has engaged Camargo Pharmaceutical Services, in order to help C-103 is a novel formulation of Orlistat, patented until 2030 in the United States....
READ MORE
|